Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MSF Biochemistry (Kaplan) > Lipid Synthesis and Storage > Flashcards

Lipid Synthesis and Storage Flashcards

1
Q

Rate-limiting enzyme of fatty acid biosynthesis

A

Acetyl CoA carboxylase (Activated by Insulin because Fat deposition is favored)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The biotin-requiring enzymes

A

The 3 “P-A-P” carboxylases: Pyruvate carboxylase (Pyruvate to OAA in Gluconeo), Acetyl CoA carboxylase (Acetyl CoA to Malonyl CoA in Fatty Acid Synthesis), and Propionyl-CoA Carboxylase (odd chain fat oxidation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The thiamine-requiring enzymes

A

The 4 “A-T-P-B” dehydrogenases: Alpha-ketoglutarate DH (TCA), Transketolase* (PPP pentose interconversion), Pyruvate DH (Pyruvate to Acetyl CoA), Branched-chain Ketoacid DH (“IVL” to Acetyl CoA and Propionyl CoA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Another name for fatty acid synthase, with the product being the only fatty acid that humans can synthesize de novo

A

Palmitate synthase (Palmitate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Required to reduce the acetyl groups added to the elongating chain in fatty acid synthesis

A

NADPH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Number of acetyl CoA required for synthesis of palmitate

A

8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cytochrome involved in the desaturation reactions in fatty acid synthesis

A

Cyt b5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

In fatty acid synthesis, double bonds can only be introduced up to what carbon position?

A

Carbon position 9 (up to 8 double bonds)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Components of TAGs

A

3 fatty acids + glycerol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tissues capable of synthesizing TAG as the storage form of fatty acids

A

Liver and Adipose tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

2 sources of glycerol-3P for TAG synthesis

A

Reduction of DHAP from glycolysis (G3P DH) in adipose (this is the only source for adipose) and liver; phosphorylation of the free glycerol released from reabsorbed VLDL (Glycerol kinase) in LIVER ONLY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diacylglycerol, inositol 1,4,5-triphosphate, and arachidonic acid are second messengers that are (biomolecule class)

A

Glycerophospholipids (differing from Glycerol by replacing one FA with 3P-Inositol)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Glycerophospholipid functioning as lung surfactant

A

Phosphatidylcholine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lightest lipoprotein

A

Chylomicrons < VLDL < IDL < LDL < HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Apoproteins of Chylomicrons

A

apoB-48, apoC-II, apoE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Apoproteins of VLDLs

A

apoB-100, apoC-II, apoE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Only apoprotein of LDL

A

apoB-100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Apoprotein of HDL

A

apoA-1 (responsible from cholesterol recovery from fatty streaks in the blood vessels)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Induced by insulin and transported to the luminal surface of capillary endothelium, hydrolyzes the fatty acids from TAGs carried by chylomicrons and VLDL

A

Lipoprotein Lipase

20
Q

Apoprotein that activates LPL

A

apoC-II

21
Q

The thoracic duct joins what vessel?

A

left subclavian vein

22
Q

Enzyme exclusively in the liver, allows liver to have an instant supply of glycerol unlike in adipose where glycerol is sourced from DHAP

A

glycerol kinase sequesters glycerol as LPL breaks down Chylomicron and VLDL TAGs

23
Q

apoC-II and apoE apoproteins are obtained by Chylomicrons and VLDLs from?

A

HDLs circulating in the blood

24
Q

Fate of the VLDL remnant, IDL

A

Some are picked up by hepatocytes through their apoE receptor for recycling, some acquire cholesterol esters from HDL particles in the blood to become LDL

25
Q

Normal role of LDL

A

Deliver cholesterol to tissues needing them for biosynthesis of bile acids and salts, steroids, etc

26
Q

Aside from de novo synthesis, hepatocytes can obtain cholesterol from/by

A

Endocytosis of LDL and Chylomicron remnants with residual dietary cholesterol, Transfer of cholesterol from HDL (via SR-B1 receptor)

27
Q

High cholesterol in hepatocytes inhibits further accumulation by reducing gene expression of

A

HMG-CoA reductase, and the LDL and SR-B1 receptors

28
Q

Protein that coats the “pit” (invagination) for endocytosis of LDL

A

clathrin

29
Q

Enzyme in the blood activated by apoA-1. It adds a fatty acid ti cholesterol to produce cholesterol esters that dissolve in the HDL core

A

Lecithin-cholesterol acyltransferase (LCAT)

30
Q

Protein that transfers HDLs’ cholesterol esters to IDLs, eventually converting the latter to LDLs

A

Cholesterol ester transfer protein (CETP)

31
Q

Receptors for HDLs that are highly expressed in tissues needing the cholesterol scavenged by HDLs along the way

A

Scavenger receptors, SR-B1, are highly abundant in hepatocytes and the steroidogenic tissues (ovaries, testes, adrenals)

32
Q

Endothelial damage, high LDL, low HDL, predisposes to what clinical condition

A

Atherosclerosis

33
Q

Special type of macrophages present in atherosclerotic plaques that takes up oxidized LDL

A

Foam cells

34
Q

Vitamin that exhibits antioxidant property in lipid phase, preventing peroxidation of membrane lipids

A

Vit E

35
Q

Rare genetic absence of LPL resulting in excess TAGs in blood and its deposition as xanthomas

A

Familial lipoprotein lipase deficiency (Type 1 Primary Hyperlipidemia). Symptoms include red-orange eruptive xanthomas, fatty liver, acute pancreatitis, abdominal pain after fatty meal

36
Q

Most common type of hyperlipidemia

A

Type V

37
Q

Lipid abnormality commonly found in diabetics

A

High triglycerides, low HDL

38
Q

Lipid abnormality in diabetics (high triglycerides) is caused by

A

Abnormally low levels of lipoprotein lipase (LPL), inability to degrade serum triglycerides in lipoproteins to facilitate uptake of FA into adipocytes

39
Q

Deficiency in Type Iia Hypercholesterolemia, characterized by elevated LDL cholesterol, increased risk for atherosclerosis, and CAD

A

LDL Receptor Deficiency. Cholesterol deposits are also seen as xanthomas of the Achilles tendon, subcutaneous tuberous xanthomas over the elbows, xanthelasma (lipid in eyelid), and corneal arcus (vs arcus senilis)

40
Q

Hypolipidemia caused by low to absent serum apoB-100 and apoB-48 (main deficiency). Serum triglycerides may be near zero, and cholesterol extremely low.

A

Abetalipoproteinemia. Steatorrhea, cerebellar ataxia, pigmentary degeneration in the retina, acanthocytes (“thorny” appearing erythrocytes), possible loss of night vision, is due to low chylomicron levels and fat accumulation in intestinal enterocytes and hepatocytes. Essential fatty acids (linoleic acid) and Vit A and E not well absorbed

41
Q

Rate-limiting enzyme in cholesterol synthesis

A

3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase; Activated by Insulin, Inhibited by Glucagon

42
Q

Product of HMG-CoA

A

Mevalonate (catalyzed by HMG-CoA reductase)

43
Q

Drug inhibitors of HMG-CoA reductase

A

Statins inhibit de novo cholesterol synthesis. Decreased hepatocyte cholesterol level will increase LDL receptor expression, more “clearing up” of the blood of LDL

44
Q

Drugs that increase elimination of bile salts, forcing liver to increase synthesis of cholesterol and to increase LDL receptor expression

A

Cholestyramine is used in the treatment of hypercholesterolemia

45
Q

An intermediate of the cholesterol synthesis pathway used for CoQ synthesis (for ETC), Dolichol pyrophosphate synthesis (cofactor in N-glycosylation in ER), and prenylation of proteins

A

Farnesyl pyrophosphate

46
Q

Side effect of statins caused by decrease in Farnesyl pyrophosphate levels due to decreased HMG-CoA reductase activity

A

Muscle soreness, pain, weakness, red-brown urine caused by myoglobinuria from damaged muscle cells. Muscle is damaged due to decreased ability to generate ATP due to decreased ETC since Farnesyl pyrophosphate is needed for synthesis of CoQ

MSF Biochemistry (Kaplan) (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions